Sign inCreate account

Report workspace tools

NCT03911700RECRUITINGanonymous

Prospective, Multi-Center, Open-Label, Randomized, Controlled Trial of Phasix™ Mesh to Prevent Incisional Hernia Subsequent to Open Midline Laparotomy

Sponsor

Source record

C. R. Bard

Phase

Source record

NA

Modality

AI-normalized

medical device

Target

AI-normalized

Incisional Hernia Prevention

Indication / condition

AI-normalized

Open Midline Laparotomy

Intervention

Source record

Phasix™ Mesh

Source & freshness

Source record

NCT ID

NCT03911700

Original source

ClinicalTrials.gov

Source last updated

Feb 25, 2026

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03911700

Title

Prospective, Multi-Center, Open-Label, Randomized, Controlled Trial of Phasix™ Mesh to Prevent Incisional Hernia Subsequent to Open Midline Laparotomy

Sponsor

C. R. Bard

Status

RECRUITING

Phase

NA

Condition raw

Open Midline Laparotomy

Condition normalized

Open Midline Laparotomy

Modality raw

Open Midline Laparotomy

Modality normalized

medical device

Target raw

Incisional Hernia Prevention

Target normalized

Incisional Hernia Prevention

Interventions

Phasix™ Mesh

Public preview

Source record

The PREVENT trial evaluates the efficacy of Phasix™ Mesh in preventing incisional hernias post-open midline laparotomy compared to standard suture closure. The trial is sponsored by C. R. Bard and is currently recruiting participants across multiple sites in the U.S. and Europe.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Prospective, Multi-Center, Open-Label, Randomized, Controlled Trial of Phasix™ Mesh to Prevent Incisional Hernia Subsequent to Open Midline Laparotomy

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03911700

Status

RECRUITING

Phase

NA

Sponsor

C. R. Bard

Executive brief

Investment-Ready Snapshot

The PREVENT trial evaluates the efficacy of Phasix™ Mesh in preventing incisional hernias post-open midline laparotomy compared to standard suture closure. The trial is sponsored by C. R. Bard and is currently recruiting participants across multiple sites in the U.S. and Europe.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 25, 2026
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03911700

Indication

Open Midline Laparotomy

Modality

medical device

Target

Incisional Hernia Prevention

Intervention

Phasix™ Mesh

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.